PALO ALTO, Calif.–(BUSINESS WIRE)– Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Blue Cross and Blue Shield of Louisiana now offers coverage for the Guardant Reveal™ molecular residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It was the first blood-only liquid biopsy test commercially available for MRD testing.
Keep Reading
Add A Comment